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Functional dependency in basic activities of daily living (ADLs) is a key outcome in Parkinson’s 
disease (PD). We aimed to define dependency in PD, using the original and MDS versions of 
the Unified Parkinson’s Disease Rating Scale (UPDRS). 
 
Methods: 
We developed two algorithms to define dependency from items of UPDRS Part 2 and MDS-
UPDRS Part 2 relating to basic ADLs (feeding, dressing, hygiene and walking, and getting out 
of a chair). We validated both algorithms using data from 1110 patients from six community-




Our optimal algorithm showed high specificity and moderate to high sensitivity versus Schwab 
& England <80% (specificity 95% [95% confidence interval (CI) 93-97] and sensitivity 65% [95% 
CI 55-73] at baseline; 88% [95% CI 85-91] and 85% [95% CI 79-97] respectively at five-years 
follow-up). Convergent validity was demonstrated by strong associations between 
dependency defined by the algorithm and cognition (MMSE), quality of life (PDQ39), and 
impairment (UPDRS part 3) (all p <0.001). Algorithm-defined dependency status also 
predicted mortality: HR for mortality in those dependent vs independent at baseline was 1.6 




We have demonstrated the concurrent validity, convergent validity, and predictive validity of 
a UPDRS-/MDS-UPDRS-based algorithm to define functional dependency in PD. This can be 





Functional dependency is an important patient-orientated outcome in Parkinson’s disease 
(PD) [1]. Here we focus specifically on dependency in terms of needing help with basic 
activities of daily living (ADLs), such as washing, dressing, toileting, feeding, or walking. 
Previous population-based studies have shown that dependency is common, even early in the 
disease course, [2,3] but there has been little research into the factors that influence this 
aspect of PD [1]. 
 
Existing dependency or activity limitation scales for PD research have drawbacks. The Schwab 
& England scale has been used most frequently but it is inherently unclear (in particular, the 
descriptor “chores” is not defined). A Schwab & England score <80% has been used as a 
definition of dependency (80%=completely independent in most chores; 70%=not completely 
independent) [3]. The Barthel Index has been used widely in other diseases, but infrequently 
in PD. Part 2 “Activities of daily living” of the Unified Parkinson’s Disease Rating Scale (UPDRS) 
and part 2 “Motor Aspects of experiences of daily living” of the Movement Disorders Society 
(MDS) revision have been used widely, but only a minority of the items in these sections relate 
to ADLs. If dependency could be identified from the UPDRS part 2, this would allow research 
into dependency in studies which have collected UPDRS data but not a specific activity 
limitation/dependency scale. We therefore aimed to develop an algorithm to identify 




We used data from the Parkinson’s Incidence Cohorts Collaboration (PICC), a project to pool 
data from six PD incidence cohorts in Northern Europe (CamPaIGN4, ICICLE-PD5, NYPUM6, 
ParkWest7, PICNICS8, and PINE9). These studies each collect demographic, clinical, and genetic 
data at time of diagnosis and at regular follow-up visits thereafter, with data on 1110 patients 
at baseline and 714 patients at approximately 5 years. Reasons for missing data at year 5 
included (i) death (N=167); (ii) loss to follow-up (N=123); (iii) participants had not reached 5-
years’ follow-up or were not seen at about 5 years (N=106). Available data included the 
original UPDRS (CamPaIGN, NYPUM, ParkWest, PINE), MDS-UPDRS (ICICLE-PD, PICNICS), 
Schwab & England scale (all studies, except not collected at baseline in PICNICS or ICICLE-PD) 
and mini-mental state examination (MMSE) (all studies), PDQ-39 (all studies except 
ParkWest), and Barthel Index (only PINE). Ethical approval for each study was obtained from 




We developed two algorithms (Table 1) to define dependency using items from UPDRS Part 2 
relating to basic ADLs (feeding, dressing, hygiene and walking in both versions and getting out 
of a chair in MDS-UPDRS). We did not include the turning in bed item from the MDS-UPDRS 
because an individual could live independently even if they were unable to turn over in bed. 
We first assessed what cut-off score for each item would necessarily indicate dependency 
based on the descriptors, i.e., if the patient had that score or higher they must have been 
dependent. For instance, for the original UPDRS hygiene item, a score of 3 (“requires 
assistance for washing, brushing teeth...”) was the lowest item which indicated definite 
evidence of dependency. The cut-offs for each item which indicated patients were clearly 
dependent are given in table 1. Algorithm 1 was defined as indicating dependency if a patient 
was clearly dependent in any one of the specified ADL items. Although a simple approach, 
this algorithm was expected to lead to under-ascertainment of dependency because of the 
ambiguity in certain descriptors for these items. For example, the original UPDRS hygiene 
score of 2 (“needs help to shower or bathe; or very slow in hygienic care”) could indicate 
dependency (“needs help to shower or bathe”) or independency (“very slow in hygienic 
care”). Algorithm 2 therefore defined dependency if either (i) any one of these ADL items 
clearly indicated dependency or (ii) the sum of these ADL items was greater than a certain 
threshold. To select the threshold we calculated specificity and sensitivity for several 
thresholds in the PINE study against a “gold standard” of dependency defined by a Barthel 
Index score of less than 16, excluding the items relating to continence as these are not specific 
ADLs. We selected the threshold with the maximal accuracy (𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠+𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
2
). We chose 
the Barthel Index as a gold standard because a score of less than 16 (after continence items 
excluded) means the patient needs help with at least one of the following ADLs: mobility, 
stairs, transfers, dressing, bathing, grooming, feeding, or toilet use. The threshold for the 




For both algorithms, we tested concurrent validity (validating against other instruments that 
measure the same concept) [10] by assessing specificity and sensitivity of the selected 
algorithm against dependency defined by Schwab & England scale <80% in each study at 
baseline (diagnosis) and at five years follow-up (4.5 years in ICICLE-PD). We chose to develop 
the algorithm 2 cut-off score using the Barthel index in PINE and validate it against the Schwab 
& England scale in all studies (rather than development using Schwab & England and 
validation using Barthel in PINE and Schwab & England in the other studies) because i) we 
wished to use an unambiguous measure of dependency for model development; ii) it allowed 
all studies to be used in the validation; and iii) it allowed a common and unbiased assessment 
of heterogeneity across all studies. 
 
We then evaluated convergent validity (evidence of correlation with similar, but not identical, 
measures) [10] by assessing associations of each algorithm with cognition (MMSE), quality of 
life (PDQ39), and parkinsonian motor impairment (UPDRS Part 3) at baseline and at 4.5-5 
years. For each association, MMSE, PDQ39 or UPDRS part 3 defined the dependent variable 
in multivariable linear regression, and the independent variables were dependency as defined 
by the particular algorithm, age at baseline and sex. 
 
We tested predictive validity by comparing mortality in those defined as dependent and 
independent by these algorithms in all six studies using Cox regression adjusted for age at 
baseline and sex. We developed Cox models with survival time measured from (i) baseline 
and (ii) the 4.5-5 year assessment until death. Patients who had not died were censored at 
the date last known to be alive. 
 
Statistical analyses were performed using SPSS version Stata version 16 and SPSS version 25.  
 
Results 
The PICC cohort included 1110 patients at baseline. Mean age was 69.5 (standard deviation 
10.0) and 61% were men. Further characteristics are found in supplementary table 1.  
 
The two algorithms are detailed in table 1. The selected thresholds for algorithm 2 were ≥6 
(original UPDRS) and ≥7 (MDS-UPDRS). Concurrent, convergent, and predictive validity are 
shown in Table 2, Supplementary Tables 2-4, and Supplementary Figures 1-3. The numbers 
included in each analysis are detailed in the supplementary tables. Algorithm 1 had only low 
to moderate sensitivities versus Schwab & England (35% [95% CI 26-44] and 58% [95% CI 51-
64] at baseline and year 5), but very high specificity (99% [95% CI 98-100] at both time points). 
Algorithm 2 had higher sensitivities (65% [95% CI 55-73] and 85% [95% CI 79-89] at baseline 
and year 5), while specificities remained high (95% [95% CI 93-97] and 88% [95% CI 85-91] at 
baseline and year 5).  
 
There were significant associations between dependency in all the constructs across both 
algorithms. Using both algorithms, those defined as dependent had significantly higher 
mortality than those independent at both time points with mortality ratios ranging from 1.6 




We have demonstrated the concurrent validity, convergent validity, and predictive validity of 
two definitions of dependency derived simply from the UPDRS/MDS-UPDRS. Although both 
algorithms had good face validity, convergent validity and predictive validity, algorithm 2 had 
better sensitivity while maintaining high specificity. We propose that algorithm 2 is a useful 
measure of functional dependency in basic ADLs but algorithm 1 may be useful as measure of 
a more-severe level of dependency. Concurrent validity was better at year 5 than at baseline, 
probably because baseline dependency relates relatively more to comorbid diseases and later 
dependency relatively more to PD-related factors; dependency items in UPDRS may be more 
specific to dependency caused by PD.  
 
This study has several key strengths. The algorithms have been validated in six prospective 
cohort studies with very low selection bias (each cohort was derived from an incidence study, 
therefore attempting to include all PD in the population). Therefore, we believe these results 
are generalizable to Caucasian populations with PD. The data were prospective with a large 
pooled sample size, and we used multiple methods in our validation.  
 
Nevertheless, this study has some limitations. We lacked a true gold standard for functional 
dependency. However, we did use validated ADL scales. The Barthel Index has been widely 
validated in assessing ADLs but has had little validation in PD [11]. Schwab and England has 
some validation data relating to activity limitation in PD but one study has suggested a score 
<80% has suboptimal sensitivity as a dichotomous dependency measure [12] despite its face 
validity. Furthermore, the Barthel data in PINE was self-reported and other scales were reliant 
on self-report if relatives/carers did not come to study visits so there may be some lack of 
objectivity. Arguably, the most accurate dependency definition would be to observe patients 
performing ADLs in their home environment, but this would be resource-intensive and time-
consuming and such data were not available. There was heterogeneity in the results between 
the individual studies included in PICC. There may several reasons for this, including small 
numbers in individual studies in some of the analyses and variability between studies in how 
some of the scales were scored. The overwhelming majority of participants were white 
European so further validation could be done in other ethnic groups.  
 
In conclusion, we have demonstrated the validity of a measure derived from the UPDRS or 
MDS-UPDRS to simply assess functional dependency in PD. It can therefore be easily applied 
in most existing clinical studies without additional data collection. Further work is needed to 
establish which ADL/dependency measure should be the gold standard for use in PD. 
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Supplementary table 1: Characteristics of incidence cohorts included in PICC 





Mean age in years of 
patients at baseline 
(SD) 
Percentage male 





CamPaiGN Cambridgeshire, UK 2000-2 142/109 70.4 (9.6) 56.3 10 
ICICLE-PD Newcastle and 
Gateshead, UK 
2009-11 154/91 66.4 (10.4) 54.9 8 
NYPUM Umeå, Sweden 2004-9 144/109 71.2 (9.9) 60.3 13 
ParkWest Western Norway 2004-6 191/160 68.1 (9.3) 61.3 8 
PICNICS Cambridgeshire, UK 2008-13 280/120 68.8 (9.7) 62.1 9 
PINE Aberdeen, UK 2002-4;06-9 199/127 70.4 (9.6) 56.3 16 
All Studies   1110/716 69.5 (10.0) 61.0 16 
  
Supplementary table 2: Concurrent validity of both algorithms at baseline and year 5.  
 Algorithm 1 Algorithm 2 
 Baseline Year 5 Baseline Year 5 
Study & comparison  
(N baseline/N year 5) 
TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, %, (CI) 
TP/TP+FN 
Sens % (CI) 
TN/TN+FP 
Spec, % (CI) 
TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, % (CI) 
TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, % (CI) 
































ICICLE-PD vs S&E <80 (NA/ 90) No data No data 11/20 
55  (32-77) 
69/70 
99 (92-100) 
No data No data 16/20 
80  (56-94) 
53/70 
76 (64-85) 








































































Abbreviations: CI=95% confidence interval; FN = false negative; FP = false positive; N=number; NA=not applicable; S&E Schwab & England scale; 
sens=sensitivity; spec=specificity; TN = true negative; TP = true positive. 
 
  
Supplementary table 3: Convergent validity of dependency algorithms versus PDQ-39, MMSE, and UPDRS/MDS-UPDRS part 3.  
 Algorithm 1 Algorithm 2 
 Baseline Year 5 Baseline Year 5 
Outcome 














PDQ-39          
  Campaign (125/103) 40.3 (26.0 – 54.5) <0.001 42.0 (30.7 – 53.2) <0.001 34.7 (28.0 – 41.5) <0.001 39.4 (29.2 – 49.6) <0.001 
  ICICLE-PD (147/88) -1.3 (-10.9 – 8.2) 0.78 30.4 (21.8 – 38.9) <0.001 0.8 (-5.2 – 6.9) 0.79 20.8 (14.3 – 27.3) <0.001 
  NYPUM (109/92) 9.5 (-8.2 – 27.2) 0.29 23.2 (13.8 – 32.5) <0.001 17.7 (8.6 – 26.7) <0.001 22.0 (15.1 – 28.9) <0.001 
  ParkWest  No data  No data  No data  No data  
  PICNICS (223/82) 25.0 (13.5 – 36.5) <0.001 28.9 (15.6 – 42.2) <0.001 27.4 (19.4 – 35.4) <0.001 34.9 (25.2 – 44.6) <0.001 
  PINE (153/102) 15.1 (9.5 – 20.7) <0.001 23.2 (13.9 – 32.5) <0.001 14.7 (10.7 – 18.7) <0.001 15.1 (9.7 – 20.5) <0.001 
  All Studies (757/467) 16.1 (11.3 – 20.9) <0.001 24.7 (20.8 –28.7) <0.001 17.4 (14.3 – 20.4) <0.001 22.7 (19.6 – 25.7) <0.001 
MMSE          
  Campaign (142 /48) -0.6 (-1.6 – 0.5) 0.30 -5.1 (-7.0 – -3.3) <0.001 -0.5 (-1.1 – 0.1) 0.11 -2.9 (-4.8 – -1.0) <0.001 
  ICICLE-PD (154/90) -0.7 (-1.5 – 0.1) 0.10 -3.4 (-5.0 – -1.7) <0.001 -0.3 (-0.9 – 0.1) 0.19 -1.4 (-2.7 – -0.1) 0.03 
  NYPUM (134 /102) -3.8 (-5.1 – -2.4) <0.001 -7.0 (-9.3 – -4.8) <0.001 -2.2(-3.2 – -1.3) <0.001 -6.3 (-8.0 – -4.6) <0.001 
  ParkWest (191/153) -2.6 (-4.3 – -0.9) 0.002 -5.5 (-7.3 – -3.6) <0.001 -1.2 (-2.5 – 0.1) 0.07 -4.4 (-5.9 – -3.0) <0.001 
  PICNICS (279/123) -0.9 (-1.6 – -0.2) 0.01 -1.8 (- 3.0 – -0.6 0.03 -0.5 (-1.0 – 0.01) 0.05 -0.9 (-1.8 – 0.1) 0.08 
  PINE (165/128) -1.8 (-2.7 – -0.8) <0.001 -4.7 (-6.7 – -2.8) <0.001 -1.1 (-1.9 – -0.4) 0.004 -3.5 (-5.4 – -1.6) <0.001 
  All Studies (1065/644) -1.5 (-1.9 – -1.0) <0.001 -4.5 (-5.3 – -3.8) <0.001 -0.8 (-1.1 – -0.5) <0.001 -2.9 (-3.5 – -2.2) <0.001 
UPDRS/MDS-UPDRS part 3         
  Campaign (139/108) 11.2 (2.1 – 20.2) 0.02 15.8 (10.3 – 21.3) <0.001 12.6 (7.7 – 17.4) <0.001 16.1 (10.7 – 21.4) <0.001 
  ICICLE-PD (153/91) 10.4 (2.7 – 18.2) 0.01 15.7 (8.8 – 22.6) <0.001 14.7 (10.3 – 19.0) <0.001 13.1 (8.3 – 18.0) <0.001 
  NYPUM (144/106) 11.1 (2.7 – 19.5) 0.01 15.7 (8.7 – 22.8) <0.001 10.8 (4.9 – 16.7) <0.001 19.4 (14.3 – 24.6) <0.001 
  ParkWest (191/159) 19.5 (12.3 – 26.8) <0.001 23.1 (18.6 – 27.6) <0.001 14.3 (8.8 – 19.9) <0.001 18.1 (14.2 – 22.0) <0.001 
  PICNICS (273/117) 11.2 (4.8 – 17.6) 0.001 11.1 (4.1 – 18.2) 0.002 10.7 (6.2 – 15.1) <0.001 16.2 (11.1 – 21.2) <0.001 
  PINE (189/130) 16.2 (11.4 – 21.0) <0.001 14.0 (10.0 – 18.0) <0.001 14.3 (10.7 – 17.9) <0.001 12.7 (8.9 – 16.4) <0.001 
  All Studies (1089/711) 13.4 (10.5 – 16.3) <0.001 15.9 (13.5 – 18.3) <0.001 12.7(10.7 – 14.6) <0.001 16.4 (14.5 – 18.3) <0.001 
Abbreviations: CI=confidence interval; MDS-UPDRS=Movement Disorders Society revision of UPDRS; MMSE=mini-mental state examination; N=number; 
PDQ-39=Parkinson’s disease questionnaire 39 item; UPDRS=unified Parkinson’s disease rating scale.  
Supplementary table 4: Predictive validity: Cox regression, hazard ratios for mortality comparing dependent with not dependent as defined by each 
algorithm. 
 Algorithm 1 Algorithm 2 
 Baseline Year 5 Baseline Year 5 
Study (N baseline/N alive at 5 
years/N total deaths/N deaths 
after year 5) 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
  Campaign (142/91/63/39) 1.46 (0.5 – 4.1) 0.48 2.5 (1.2 – 5.1) 0.01 2.0 (1.1 – 3.4) 0.02 2.6 (1.1 – 5.9) 0.03 
  ICICLE-PD (154/92/28/6) 3.0 (1.1 – 8.0) 0.03 1.8 (0.2 – 14.8) 0.61 4.6 (0.8 – 27.5) 0.09 3.7 (0.4 – 38.4) 0.27 
  NYPUM (144/106/77/42) 2.18 (0.87 – 5.4) 0.09 3.4 (1.6 – 7.0) 0.01 2.6 (1.3 – 5.1) 0.01 2.7 (1.4 – 5.4) 0.01 
  ParkWest (191/90/34/9) 0.63 (0.1 – 2.8) 0.54 10.1 (2.2 – 45.4) 0.003 1.02 (0.3 – 3.1) 0.97 6.3 (1.4 – 28.4) 0.002 
  PICNICS (280/79/50/10) 1.31 (0.5 – 3.8) 0.62 2.4 (0.5 – 12.6) 0.31 1.8 (0.8 – 4.3) 0.17 2.0 (0.5 – 7.7) 0.31 
  PINE (199/140/149/90) 1.47 (1.01 – 2.8) 0.05 1.8 (1.1 – 2.9) 0.02 1.2 (0.8 – 1.8) 0.45 1.6 (1.0 – 2.6) 0.06 
  All Studies (1110/598/401/196) 1.7 (1.2 – 2.3) 0.002 2.6 (1.9 – 3.5) <0.001 1.6 (1.2 – 2.1) <0.001 2.2(1.6 – 3.0) <0.001 
Abbreviations: CI=confidence interval; HR=hazard ratio; N=number.  
  
Supplemental figure 1: Scatterplots showing association between dependency status (defined by each algorithm) and the three factors used to assess convergent 
validity at baseline. Data from all studies were included, where available. The red line illustrates the predicted values from the model (i.e. the average adjusted values 
from the model according to dependency status).  
  
Supplemental figure 2: Scatterplots showing association between dependency status (defined by each algorithm) and the three factors used to assess convergent 
validity at year 5. Data from all studies were included, where available. The red line illustrates the predicted values from the model (i.e. the average adjusted values 
from the model according to dependency status).  
  
Supplemental figure 3: Kaplan-Meier plots of survival from baseline in those defined as independent or dependent by algorithm 1 (A) and algorithm 2 (B) and survival 
from year 5 in those defined as independent or dependent by algorithm 1 (C) and algorithm 2 (D). 
 
Scale version Item  Individual 
item threshold 
Threshold for sum of items for 
additional use in Algorithm 2 
Original UPDRS 2.9 – Cutting food ≥3 ≥6 (out of 16) 
 2.10 – Dressing ≥3  
 2.11 – Hygiene ≥3  
 2.15 – Walking ≥3  
MDS-UPDRS 2.4 – Cutting food ≥3 ≥7 (out of 20) 
 2.5 – Dressing ≥3  
 2.6 – Hygiene ≥2  
 2.11 – Getting out of a chair ≥3  
 2.12 – Walking ≥4  
Table 1 – Thresholds for UPDRS ADL items used to develop the algorithms. Algorithm 1 defines 
dependency if a patient is necessarily dependent in any of the individual items, defined by the stated 
threshold for each item. Algorithm 2 defines dependency if a patient is necessarily dependent in any 
of the individual items (third column) OR if the sum of the individual items meets the stated 
threshold (fourth column). 
 Algorithm 1 Algorithm 2 
 Baseline Year 5a Baseline Year 5a 
Concurrent validity TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, %, (CI) 
TP/TP+FN 
Sens % (CI) 
TN/TN+FP 
Spec, % (CI) 
TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, % (CI) 
TP/TP+FN 
Sens, % (CI) 
TN/TN+FP 
Spec, % (CI) 











































 (95% CI) 
P-value 
  PDQ-39  16.1 (11.3 – 20.9) <0.001 24.7 (20.8 –28.7) <0.001 17.4 (14.3 – 20.4) <0.001 22.7 (19.6 – 25.7) <0.001 
  MMSE  -1.5 (-1.9 – -1.0) <0.001 -4.5 (-5.3 – -3.8) <0.001 -0.8 (-1.1 – -0.5) <0.001 -2.9 (-3.5 – -2.2) <0.001 
  UPDRS/MDS-UPDRS part 3 13.4 (10.5 – 16.3) <0.001 15.9 (13.5 – 18.3) <0.001 12.7(10.7 – 14.6) <0.001 16.4 (14.5 – 18.3) <0.001 

















All studies 1.7 (1.2 – 2.3) 0.002 2.6 (1.9 – 3.5) <0.001 1.6 (1.2 – 2.1) <0.001 2.2 (1.6 – 3.0) <0.001 
 
Table 2: Concurrent validity, convergent validity, and predictive validity of the two dependency algorithms. a4.5 years in ICICLE-PD. bAdjusted difference represents the 
difference in score between dependent and independent as defined by the algorithm, adjusted for age and sex. A positive difference in PDQ-39 score indicates worse 
quality of life, a negative difference in MMSE indicates poorer cognition and a positive difference in UPDRS part 3 indicates a more severe motor impairment in those who 
are dependent. Abbreviations: CI = confidence interval; FN = false negative; FP = false positive; HR = hazard ratio; MDS-UPDRS = Movement Disorder Society revision of 
the Unified Parkinson’s disease rating scale; MMSE = mini-mental state examination; PDQ-39 = Parkinson’s disease questionnaire – 39 item; S&E = Schwab & England; TN = 
true negative; TP = true positive; UPDRS = Unified Parkinson’s disease rating scale.  
